TITLE:
A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer

CONDITION:
Breast Cancer

INTERVENTION:
capecitabine [Xeloda]

SUMMARY:

      This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere
      alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer.
      Following 4 cycles of Adriamycin and Cytoxan, patients will be randomized to receive either
      1)Taxotere 75mg/m2 iv on day 1 and Xeloda 825mg/m2 po bid on days 1-14 of each 3 week cycle
      or 2) Taxotere 100mg/m2 iv alone on day 1 of each 3 week cycle. The anticipated time on
      study treatment is until disease progression, and the target sample size is 500+
      individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to 70 Years
Criteria:

        Inclusion Criteria:

          -  female patients 18-70 years of age;

          -  adenocarcinoma of the breast;

          -  previous invasive breast cancer if diagnosed >5 years before entering study;

          -  no evidence of metastatic disease.

        Exclusion Criteria:

          -  history of severe hypersensitivity reaction to Taxotere;

          -  previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane;

          -  treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.
      
